Los Altos, California, United StatesFounded 201979+ employeesANRO
$421M raisedIPO· last: post ipo equity (Mar 2026)· 13 rounds
Backed by(38 investors)
Perceptive Advisors · LeadCommodore Capital · LeadAlkeon Capital · LeadAlpha Wave Ventures · LeadApeiron Investment Group · LeadInVivium Capital · LeadK2 HealthVentures · LeadLightswitch Capital · LeadTim Kendall · LeadWellcome Trust · Lead+9 more
Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.
